Packer M et al., SUMMIT, NEJM 2024 (NEJMoa2410027, PMID 39555826) : tirzepatide and HFpEF with obesity, HR 0,62 composite endpoint
How It Works on the Skin The treatment uses very fine needles to inject a special mixture of ingredients into the middle layer of your skin
Aging, Biomarker, Consortium et al
Muscle loss is already a common concern for people taking GLP-1s (for more on this, read Muscle Preservation on GLP-1s: Strategies to Safeguard Lean Mass During Weight Loss )
No receptor downregulation
Under your doctors guidance, the dose increases in phases from 2 mg to 4 mg, 8 mg, and up to 12 mg per week